微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 30.2% | -18.59% | -6.87% | 112/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 32.43% | -17.37% | -2.61% | 110/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 33.29% | -16.11% | -7.61% | 109/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 36.03% | -9.08% | -2.86% | 104/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 37.1% | -9.02% | -5.47% | 99/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 39.24% | 2.39% | -1.12% | 103/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 39.69% | 2.08% | 0.14% | 100/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 39.63% | 1.17% | -2.8% | 98/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 40.77% | 0.65% | 6.39% | 92/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 38.33% | 0.65% | -1.42% | 109/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 38.88% | -2.21% | -0.74% | 106/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 39.17% | -3.52% | -3.3% | 105/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 40.51% | -4.96% | 6.38% | 96/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 38.08% | -12.9% | -4.22% | 105/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 39.76% | -10.11% | -2.08% | 98/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 40.6% | -6.62% | -4.74% | 96/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 42.62% | -6.42% | -2.51% | 90/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 43.72% | -7.13% | -1.15% | 91/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 44.23% | -4.65% | 1.72% | 81/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 43.48% | -3.96% | -4.53% | 87/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 45.55% | 3.83% | -3.25% | 74/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 47.08% | -5.24% | 1.48% | 86/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 46.39% | -9.57% | 2.46% | 77/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 45.27% | -11.8% | 3.21% | 85/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 43.87% | -15.73% | -11.7% | 76/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 49.68% | 1.85% | -3.16% | 78/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 51.3% | 2.74% | -0.06% | 59/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 51.33% | 5.35% | -1.39% | 61/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 52.05% | 8.02% | 6.72% | 54/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 48.78% | 12.56% | -2.31% | 74/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 49.93% | 26.99% | 2.48% | 54/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 48.72% | 26.51% | 1.11% | 57/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 48.19% | 22.29% | 11.21% | 57/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 43.33% | 19.87% | 10.21% | 73/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 39.32% | 9.38% | 2.09% | 59/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 38.51% | 6.48% | -2.26% | 66/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 39.41% | 9.57% | 9.01% | 48/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 36.15% | 3.71% | 0.56% | 76/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 35.95% | -25.38% | -0.62% | 51/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 36.17% | -25.12% | 0.58% | 58/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 35.96% | -21.51% | 3.18% | 50/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |